Novartis: Alzheimer Disease trials
The registry lists 36 Alzheimer Disease studies with Novartis as lead sponsor. 0 are open to participants now and 17 have results posted.
Phase 1 2Phase 2 11Phase 3 11Phase 4 14(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's DiseaseTerminatedNCT04795466Phase 2Results posted
- A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseTerminatedNCT03131453Phase 2/3Results posted
- A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.CompletedNCT02989402Phase 4Results posted
- NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.CompletedNCT02703636Phase 4Results posted
- Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of AgeCompletedNCT02576639Phase 2Results posted
- A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseTerminatedNCT02565511Phase 2/3Results posted
- 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease PatientsCompletedNCT01948791Phase 4Results posted
- Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)CompletedNCT01614886Phase 3Results posted
- Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's DementiaCompletedNCT01585272Phase 4Results posted
- A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's DiseaseCompletedNCT01399125Phase 3Results posted
- Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44CompletedNCT00948766Phase 4Results posted
- A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)CompletedNCT00622713Phase 4Results posted
- Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's DiseaseCompletedNCT00561392Phase 4Results posted
- Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00549601Phase 4Results posted
- Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive DeclineCompletedNCT00506415Phase 3Results posted
- Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00428389Phase 3Results posted
- Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00423085Phase 3Results posted
- A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's DiseaseActive, not recruitingNCT07094516Phase 2
- Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive, not recruitingNCT05469360Phase 1
- Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase InhibitorsCompletedNCT01529619Phase 4
- Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer PatientsCompletedNCT01097096Phase 2
- A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's DiseaseCompletedNCT01047579Phase 4
- To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsCompletedNCT01023685Phase 2
- To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsCompletedNCT00956410Phase 2
- Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's PatientsCompletedNCT00795418Phase 2
- Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.CompletedNCT00733863Phase 2
- Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.CompletedNCT00731224Phase 4
- Effect of AQW051 in Patients With Memory ImpairmentTerminatedNCT00582855Phase 2
- Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00411580Phase 1
- Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's DiseaseCompletedNCT00305903Phase 4
- Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor TreatmentCompletedNCT00234637Phase 4
- An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00219232Phase 3
- Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive ImpairmentTerminatedNCT00134953Phase 3
- Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's DiseaseCompletedNCT00104442Phase 4
- Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00099242Phase 3
- Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)CompletedNCT00000174Phase 3